Related Experiment Videos

Molecular modelling of 17 alpha-hydroxylase-17,20-lyase

A Schappach1, H D Höltje

  • 1Institute of Pharmaceutical Chemistry, Heinrich Heine University, Düsseldorf, Germany.

Die Pharmazie
|July 12, 2001
PubMed

Insights

Researchers developed a 3D model of human 17 alpha-hydroxylase-17,20-lyase, crucial for androgen biosynthesis. This computational model aids understanding of hormone-dependent cancers and potential new therapies.

Area of Science:

  • Biochemistry
  • Computational Biology
  • Drug Discovery

Background:

  • Hormone-dependent cancers, such as prostate and breast cancer, are significant research areas.
  • Inhibiting hormone biosynthesis is a promising therapeutic strategy for these cancers.
  • The enzyme 17 alpha-hydroxylase-17,20-lyase is key to androgen biosynthesis, but its structure is unknown.

Purpose of the Study:

  • To create a theoretical 3D model of human 17 alpha-hydroxylase-17,20-lyase.
  • To investigate the enzyme's structure, function, and substrate binding site.
  • To provide insights for developing novel cancer therapies.

Main Methods:

  • Homology modeling using P450 CYPeryF crystal structure as a template.
  • Energy minimization and molecular dynamics simulations (GROMACS) for model refinement and stability assessment.
  • GRID program for active site characterization and docking studies with pregnenolone.

Main Results:

  • A refined 3D model of human 17 alpha-hydroxylase-17,20-lyase with good protein geometry and folding quality was generated.
  • Molecular dynamics simulations confirmed the model's stability under physiological conditions.
  • Putative binding sites for physiological substrates were identified through docking and molecular dynamics of protein-substrate complexes.

Conclusions:

  • The developed 3D model offers valuable insights into the structure and function of 17 alpha-hydroxylase-17,20-lyase.
  • This computational approach advances the understanding of androgen biosynthesis.
  • The findings support the development of targeted therapies for hormone-dependent cancers.

Related Concept Videos